Common gout drug tested to fight Obesity's hidden inflammation

NCT ID NCT05017571

Summary

This study tested whether a low daily dose of colchicine, an anti-inflammatory drug used for gout, could improve how the body processes sugar in people with obesity. Researchers enrolled 152 adults and adolescents who were overweight, had signs of body-wide inflammation, and high insulin levels but not yet diabetes. Participants took either colchicine or a placebo pill daily for 12 weeks to see if it reduced insulin resistance.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

Conditions

Explore the condition pages connected to this study.